drugset
drugset / Trial / NCT04802785

The Impact of Air Travel on Passenger Cognitive Functions

NCT04802785 ↗

Phase 2/3 Unknown 50 enrolled Dinara Zhumanbayeva
RandomizedParallel-groupOpen-labelPrevention

Summary

In the period from June 2021 to June 2022, a prospective clinical study will be conducted in the Republic of Kazakhstan with economy class passengers traveling by plane with a minimum flight period of 5-7 flight hours in the territory of the Republic of Kazakhstan.

Timeline

Start
2021-06
Primary completion
2021-07
Completion
2022-05

Drugs

EvaluationDrugModalityDoseRoute
Subject 1 capsule per os. Unknown — Oral
Subject 3-4 capsules per os Unknown — Oral
Subject Aspirin Small molecule 150 mg Oral
Subject Citicoline Other / unclassified 500 mg Oral
Subject Cytochrome C6 Unknown 10 mg Oral
Subject Dextrose Unknown 13.5 g Oral
Subject Domperidone Unknown — Oral
Comparator Melatonin Small molecule 5 mg Oral
Subject Potassium Chloride Small molecule 1.5 g Oral
Subject magnesium hydroxide Unknown 30 mg Oral
Subject sodium chloride Unknown 2.6 g Oral
Subject sodium citrate Unknown 2.9 g Oral

Indications

No indication recorded.